FIG 2.

Bryostatin-1 and romidepsin decrease HIV-1 cellular receptors. (A) MDMs were treated with LRAs for 6 h (circles) or 24 h (red squares), and CCR5 (left) or CD4 (right) gene expression was quantified by RT-qPCR. Minimum, mean, and maximum values are represented by horizontal lines. Data were normalized on 18S gene expression for each donor and expressed as fold change over the untreated condition (n = 5). (B) MDMs were treated with LRAs for 24 h and were next analyzed for CCR5 (left) and CD4 (right) membrane expression by flow cytometry. Results are represented as the percentage of positive cells for CCR5 or as the mean fluorescence intensity (MFI) relative to untreated cells for CD4 (n = 4). One-way ANOVA with Dunnett’s multiple-comparison test was used (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005; ****, P ≤ 0.001).